StockNews.AI
CAPR
StockNews.AI
34 days

Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Capricor Stockholders and Encourages Investors to Contact the Firm

1. Bragar Eagel & Squire is investigating Capricor for potential legal violations. 2. Capricor's stock has seen significant declines after FDA-related announcements. 3. An advisory committee meeting for deramiocel was canceled due to safety concerns. 4. Investors are encouraged to explore possible claims against Capricor. 5. Legal inquiries may further impact Capricor's stock performance and investor confidence.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The ongoing legal investigation and stock declines paint a negative outlook for CAPR. Historically, similar investigations can lead to increased volatility and loss of investor trust, as seen with other biotech firms facing legal challenges.

How important is it?

The article highlights current legal investigations that could significantly undermine Capricor's share value. The potential for ongoing or new claims signals a material risk for current and prospective investors, enhancing its importance.

Why Short Term?

The immediate impact may be significant due to public sentiment and stock performance. As legal proceedings materialize or reports develop, investor reactions are likely to fluctuate rapidly, as seen with other biotech stock events.

Related Companies

SPPINTLACRIS
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Capricor (CAPR) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Capricor and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ:CAPR) on behalf of Capricor stockholders. Our investigation concerns whether Capricor has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On May 5, 2025, Capricor issued a press release announcing that after "the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy", the FDA had "confirmed its intent to hold an advisory committee meeting" in connection with the BLA. On this news, Capricor's stock price fell $3.00 per share, or 29.13%, to close at $7.30 per share on May 6, 2025. Then, on June 20, 2025 the publication STAT reported that the new head of the relevant FDA unit had canceled the advisory committee meeting for deramiocel due to uncertainty about the drug's efficacy and safety. On this news, Capricor's stock price fell $3.68 per share, or 30.82%, to close at $8.26 per share on June 20, 2025. If you purchased or otherwise acquired Capricor shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

Related News